Fresenius Medical Care was formed 25 years ago, and we are now the world’s largest dialysis provider. Join us as we celebrate our achievements and look ahead to the next 25 years of possibilities. For patients. For employees. For healthcare.
content list
1995
1996
1997
1990's
1996
Fresenius Medical Care North America (FMCNA) was formed with the merger of Fresenius USA, Inc., and National Medical Care’s North American dialysis business, becoming the continent’s leading dialysis provider and renal products manufacturer.
Launched the Advanced Renal Education Program (AREP) to assist nephrologists and professional dialysis staff in improving clinical outcomes and standards of practice.
2006
Entered the renal pharmaceuticals market with the acquisition of phosphate binder PhosLo®. PhosLo is a calcium acetate phosphate binder for oral application in end stage renal disease patients.
2006
Acquired dialysis provider Renal Care Group, a specialized dialysis services company that provided care to patients with kidney disease.
2008
Entered into a licensing agreement for Venofer® to treat iron deficiency anemia experienced by dialysis patients.
2009
Fresenius Renal Pharmaceuticals launched an authorized generic equivalent of PhosLo in partnership with Sandoz Pharmaceutical company.
2009
Acquired Nashville-based Health IT Services Group, bringing Acumen nEHR — the first nephrology-specific electronic health record — into the organization.
2009
Launched FreseniusRx , enabling patients to order and receive medications and supplies directly from specially trained renal pharmacists.
2010
2012
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2010's
2010
Extended cooperation with pharmaceutical company Galencia and founded Vifor Fresenius Medical Care Renal Pharma (VFMCRP), to develop and market pharmaceutical therapies for patients with chronic kidney disease.
Fresenius Renal Pharmaceuticals launched Velphoro®, a phosphate binder used in the treatment of hyperphosphatemia in patients who receive dialysis.
2014
Acquired National Cardiovascular Partners, the leading operator of endovascular, vascular, and cardiovascular services in the outpatient setting.
2016
Renal Therapies Group introduced the CLiC™ device, part of the Crit-Line® technology product line. The CLiC device non-invasively measures hematocrit, oxygen saturation, and percent change in intravascular blood volume during a patient’s hemodialysis treatment.
2016
Launched Fresenius Kidney Care as a division of Fresenius Medical Care North America, focused on education for people at all stages of kidney disease and dialysis services.
Partnered with Cigna to launch a national program to drive quality and lower the cost of care for people with end stage renal disease undergoing dialysis.
2017
During a record-setting hurricane season, our Disaster Response Team mobilized ahead of hurricanes Irma, Harvey, and Maria, ensuring our dialysis patients received the life-sustaining care they needed and our employees were safe and supported.
2017
Launched Fresenius Kidney Care’s kidney disease education class, a free, expert-led class that helps people learn more about kidney disease and their treatment options — including transplant and home dialysis.
2018
Fresenius Medical Care and Humacyte, Inc. — a medical research, discovery, and development company focused on regenerative medicine — announced a strategic global partnership.
2018
Launched the Fresenius Medical Care Foundation, a nonprofit created to address the environmental, social, and economic conditions that increase the risk for chronic kidney disease.
2019
Broke ground on a new distribution center in Knoxville, TN, supporting efforts to increase the supplies and timing for the growing number of patients who choose home dialysis.
2019
Invested in BioIntelliSense, to improve remote patient monitoring, interventions, and outcomes for people living with kidney disease and other chronic illnesses.
